NCT06080789 - A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Acute Pancreatitis

Interventions

DRUG

RABI-767

125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.

Trial Locations (12)

10016

RECRUITING

NYU Langone Medical Center, New York

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

32608

RECRUITING

University of Florida Health, Gainesville

32806

RECRUITING

Orlando Health, Orlando

46202

RECRUITING

Indiana University Health University Hospital, Indianapolis

48202

RECRUITING

Henry Ford Hospital, Detroit

60612

RECRUITING

UI Health, University of Illinois Chicago Hospital Health Sciences System, Chicago

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

90033

RECRUITING

Keck Hospital of USC and LA County Hospital, Los Angeles

682018

RECRUITING

Lisie Hospital, Kochi

03756

RECRUITING

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors

lead

Panafina, Inc.

INDUSTRY